| Biomarker ID | 1216 |
| PMID | 24081904 |
| Year | 2014 |
| Biomarker | Cytochrome P450 family 24 subfamily A member 1 (CYP24A1) |
| Biomarker Basis | Expression Based |
| Biomolecule | mRNA |
| Source | Tissue |
| Subjects | Humans |
| Regulation | Upregulated in PCa (4 fold) |
| Odds Ratio/Hazard Ratio/Relative Risk | NA |
| Effect on Pathways | Pathways include: Vitamin D biosynthesis, Vitamin D (calciferol) metabolism, Cytochrome P450 metabolism of vitamins, Steroid hormone, vitamin A, and vitamin D metabolism, Nuclear receptors in lipid metabolism and toxicity |
| Experiment | Prostate Cancer Vs Benign Prostatic Hyperplasia |
| Type of Biomarker | Diagnostic |
| Cohort | 29 prostate cancer and 7 benign tissues were used for analysis |
| Senstivity | NA |
| Specificity | NA |
| AUC | NA |
| Accuracy | NA |
| Level Of Significance | p = 0.03 |
| Method Used | qPCR |
| Clinical | No |
| Remarks | NA |
| Clinical Trial Number | NA |
| Degree Of Validity | Validated on independent patient dataset |
| Technical Name | CYP24A1 |